 |
I had the honor of giving two talks at a conference organized by the Japanese HBOC Consortium in Tokyo: one for patients and the other for health care providers. It was an incredible eye-opening experience that helped me appreciate how far we have come in research, clinical care, and resources for the HBOC community in the United States in last 16 years since FORCE was founded. You can read my blog with highlights from my presentation.
Be empowered and be well,
Sue Friedman, Executive Director
|
|
2015 FORCE Conference Registration Open & Scholarship Applications Accepted Until March 1st
|  |
|
|
Be one of the more than 700 participants June 18-20, 2015, at the Philadelphia Downtown Marriott for the 9th annual Joining FORCEs conference. The program will present a wide range of topics and provide an opportunity to connect with others who are travelling your same journey. It's a not-to-be-missed experience! You can help us spread the word by ordering and sharing conference brochures with family, friends, and health care providers. We are still accepting applications and donations for the conference scholarship fund. The deadline to apply is March 1st.
"Attending the conference was like a dream. I was in awe of the session topics and felt star-struck by the amazing doctors and professionals there to speak. After attending the conference, I felt empowered, confident, and hopeful."
Anne Embrey, FORCE Constituent and BC Survivor
Register Today
|
|
Last Call - Bibs for the ASICS Los Angeles Marathon
| |
|
If you are ready for a challenge, run the ASICS Los Angeles Marathon, scheduled for March 15, 2015. We still have a few bibs remaining, so act quickly to reserve your spot. And stay tuned for more exciting opportunities to become a part of TeamFORCE in the coming months.
Contact Team FORCE for more information
|
|
Help Accelerate Hereditary Cancer Research by Joining ABOUT Network Research Registry
| |
|
ABOUT Network Research Registry
FORCE is dedicated to advancing HBOC research. To help us succeed, we have launched the ABOUT Network: the first national research registry created by and for the HBOC community. You can help us transform hereditary cancer research and improve outcomes by joining the registry and sharing your real-world health care experiences.
|
|
FORCE is Growing - We Are Looking For a Director of Development
| |
|
FORCE is looking for an experienced Director of Development to join our team. The position will oversee our annual giving and other fundraising programs. If you have the right qualifications and want to help the hereditary breast and ovarian cancer community, view the job description below and apply directly, or send your resume to careers@facingourrisk.org. Please do not respond to this email or send your resume directly to FORCE staff members.
|
|
Survey for Previvors with a BRCA Mutation
| |
|
Survey on risk reduction options for BRCA1 or BRCA2 positive women who have never had cancer
RTI International, a nonprofit research organization, is recruiting women to participate in an opinion survey. The survey will ask you questions about your experience living with a BRCA1 or BRCA2 mutation, and your opinions about current and potential treatments that can reduce the risk of developing breast or ovarian cancers. To help with this research, please use the link below to take this survey. The survey is open to women who have tested positive for a mutation in BRCA1 or BRCA2 genes, age 25-55, with no previous diagnosis of breast or ovarian cancer.
|
|
Hereditary Cancer Treatment Clinical Trials
| |
|
Ovarian Cancer Treatment Study
-
NOVA is a maintenance trial for women with ovarian cancer to find out if niraparib (a PARP inhibitor) can help delay worsening in patients who had a good response to previous treatment with a platinum-type chemotherapy.
Breast Cancer Treatment Studies
-
The EMBRACA trial is a Phase III study from BioMarin, with talazoparib, a PARP inhibitor, in patients with locally advanced and/or metastatic breast cancer with a BRCA mutation.
-
OlympiAD is a phase III study comparing how olaparib (a PARP inhibitor) works compared to standard chemotherapy in patients with HER2 negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Patients will be randomized 2 to 1, so patients will be twice as likely to receive olaparib than standard chemotherapy. Patients who may be eligible for the study but do not know their BRCA mutation status will be tested at no expense.
- BRAVO is a trial for men and women who have HER2 negative, BRCA mutation positive breast cancer that progressed after prior treatment. BRAVO will compare niraparib (a PARP inhibitor) with standard chemotherapy.
Visit our research page for other HBOC studies
|
|
|
|
|
FORCE Video Series - One Minute Can Save a Life
| |
|
|
|
Clinical trials and research studies are critical to improving care for those in the HBOC community. There is a real need for better prevention, surveillance and treatment options and you can help us get there. Participate in research where it makes sense for you and share this month's "One Minute Can Save a Life" video, Research is the Key to Our Future, with anyone who could benefit from its life-saving message.
 | |
Research is the Key to Our Future
|
|
|
|
 |
|
